Amgen Inc and Cytokinetics Inc said on Tuesday their experimental drug for chronic heart failure showed significant improvement in cardiac function in the second part of a mid-stage study.

The 448 patients in the trial were given an oral formulation of the drug omecamtiv mecarbil for 20 weeks and observed for 24 weeks, the companies said in a joint statement.

An intravenous formulation of the drug failed in 2013, leaving its future uncertain. The tests on the oral formulation ran longer than the tests on the intravenous formulation and the results will determine if the drug moves into late-stage tests or is discontinued.

Heart failure, in which heart muscles are unable to pump enough blood around the body, is often a deadly disease. About half of people diagnosed with the condition die within five years and treatments have changed little since the 1970s.

To read the full release, please go here.